UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000031136 |
|---|---|
| Receipt number | R000035567 |
| Scientific Title | A multicenter, open-label, randomized controlled trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries |
| Date of disclosure of the study information | 2018/03/01 |
| Last modified on | 2023/08/13 11:55:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A multicenter, open-label, randomized controlled trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries
Acronym
A randomized controlled trial comparing the target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries
Scientific Title
A multicenter, open-label, randomized controlled trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries
Scientific Title:Acronym
A randomized controlled trial comparing the target values for lipid management in patients who have mild to moderate stenosis lesions with high-risk plaques in coronary arteries
Region
| Japan |
Condition
Condition
Conditions having mild to moderate stenosis lesions with high-risk plaques in coronary arteries, but not yet developing ischemic heart disease
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To prove whether a strict lipid management according to the secondary prevention criteria for high-risk patients can reduce coronary events or stenosis progression in patients who have mild to moderate stenosis lesions with unstable plaque or severe calcification in coronary arteries detected on coronary artery CT, but have not yet developed ischemic heart disease
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Composite endpoint: major cardiovascular events (death from coronary artery disease, nonfatal myocardial infarction, operation of coronary revascularization, stroke) and stenosis progression or new stenosis development
Key secondary outcomes
All-cause deaths (deaths from cardiac causes or non-cardiac causes, deaths from an unknown cause), ACS onset (nonfatal myocardial infarction, unstable angina), operation of coronary revascularization, stenosis progression or new stenosis development, calcification exacerbation, stroke (atherothrombotic cerebral infarction, cardiogenic cerebral embolism, cerebral hemorrhage), adverse event (AE)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
No need to know
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Behavior,custom |
Interventions/Control_1
Control (Group A); target values for LDL-C are 100 ~ < 120 mg/dL for high risk category, 120 ~ < 140 mg/dL for medium risk category, and 140 ~ < 160 mg/dL for low risk category, according to the primary prevention criteria based on the JAS Guidelinefor Prevention of Atherosclerotic Cardiovascular Diseases
Interventions/Control_2
Intervention (Group B); target value for LDL-C is < 70 mg/dL, according to the secondary prevention criteria for high-risk patients based on the JAS Guideline for Prevention of Atherosclerotic Cardiovascular Diseases
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Patients with mild to moderate stenosis lesions with positive remodeling (Remodeling Index [RI] >= 1.1) in the trunk, branches or periphery of coronary arteries with a diameter of 2 mm or more, or with advanced coronary artery calcification (Coronary Artery Calcification Score) [CACS]> 400), detected on coronary artery CT.
2)Aged 20 years or more at the time of consent
3)Provided written consent by their free will
Key exclusion criteria
1)With a significant stenosis of the coronary artery which is an indication for revascularization
2)Having a history of myocardial infarction
3)Having a history of coronary artery revascularization (PCI or CABG)
4)Whose LDL-C value already satisfies the secondary prevention criteria in JAS Guideline for Prevention of Atherosclerotic Cardiovascular Diseases at the time of registration
5)Diagnosed with familial hypercholesterolemia-homozygote
6)With poorly controlled diabetes whose HbA1c value is 10% or more
7)With BMI of less than 17 kg/m2
8)With chronic kidney disease whose eGFR value is 30 mL/min/1.73 m2 or less
9)Having a history of complications suspected to be related to the contrast medium
10)With thyroid disease requiring treatment
11)Confirmed bronchial asthma, multiple myeloma, macroglobulinemia, tetany, or pheochromocytoma
12)Having a history of side effects caused by taking statins
13)In poor compliance with medication due to dementia
14)Judged to be inappropriate for participation in this study by the principal investigator/sub-investigators
Target sample size
740
Research contact person
Name of lead principal investigator
| 1st name | Morihiro |
| Middle name | |
| Last name | Matsuda |
Organization
National Hospital Organization Kure Medical Center
Division name
Institute for Clinical Research
Zip code
737-0023
Address
3-1, Aoyama-cyo, Kure-shi, Hiroshima, 737-0023 Japan
TEL
0823-22-3111
mmatsuda.kmc@gmail.com
Public contact
Name of contact person
| 1st name | Morihiro |
| Middle name | |
| Last name | Matsuda |
Organization
National Hospital Organization Kure Medical Center
Division name
Institute for Clinical Research
Zip code
737-0023
Address
3-1, Aoyama-cyo, Kure-shi, Hiroshima, 737-0023 Japan
TEL
0823-22-3111
Homepage URL
mmatsuda.kmc@gmail.com
Sponsor or person
Institute
National Hospital Organization Kure Medical Center
Institute
Department
Personal name
Funding Source
Organization
National Hospital Organization
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Hospital Organization Kure Medical Center
Address
3-1, Aoyama-cyo, Kure-shi, Hiroshima, 737-0023 Japan
Tel
0823-22-3111
yamamoto.hatsue.ve@mail.hosp.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
北海道医療センター（北海道）、函館病院（北海道）、北海道がんセンター（北海道）、水戸医療センター（茨城県）、埼玉病院（埼玉県）、横浜医療センター（神奈川県）、相模原病院（神奈川県）、金沢医療センター（石川県）、京都医療センター（京都府）、大阪医療センター（大阪府）、岡山医療センター（岡山県）、呉医療センター（広島県）、岩国医療センター（山口県）、神戸医療センター（兵庫県）、福山医療センター（広島県）、愛媛医療センター（愛媛県）、九州医療センター（福岡県）、熊本医療センター（熊本県）
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
95
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2018 | Year | 03 | Month | 05 | Day |
Date of IRB
| 2017 | Year | 11 | Month | 15 | Day |
Anticipated trial start date
| 2018 | Year | 03 | Month | 20 | Day |
Last follow-up date
| 2023 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 02 | Month | 04 | Day |
Last modified on
| 2023 | Year | 08 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035567
